De novo 2p16.1 microdeletion with metastatic esophageal adenocarcinoma

Research output: Contribution to journalArticle

Abstract

Microdeletions involving chromosome 2p15-16.1 are a rare genetic abnormality and have been reported in 18 separate patients, mainly children, since 2007. This microdeletion syndrome is characterised by a heterogeneous expression of intellectual impairment, dysmorphic facies, musculoskeletal abnormalities and potential neurodevelopmental anomalies. We report the first case of natural progression in an adult patient who died at a young age of metastatic esophageal adenocarcinoma. Important learning points include the variable phenotypic expression of this microdeletion syndrome and the fact that clinicians must be thorough in investigating objective discrepancies in patients who cannot endorse classical symptoms.

Original languageEnglish (US)
Article numberbcr2016218016
JournalBMJ Case Reports
Volume2017
DOIs
StatePublished - 2017

Fingerprint

Adenocarcinoma
Musculoskeletal Abnormalities
Chromosomes
Learning

ASJC Scopus subject areas

  • Medicine(all)

Cite this

De novo 2p16.1 microdeletion with metastatic esophageal adenocarcinoma. / Codipilly, Don Chamil; Gavrilova, Ralitza M; Tangalos, Eric George.

In: BMJ Case Reports, Vol. 2017, bcr2016218016, 2017.

Research output: Contribution to journalArticle

@article{7bc71935b0d24ecca122e02d01773912,
title = "De novo 2p16.1 microdeletion with metastatic esophageal adenocarcinoma",
abstract = "Microdeletions involving chromosome 2p15-16.1 are a rare genetic abnormality and have been reported in 18 separate patients, mainly children, since 2007. This microdeletion syndrome is characterised by a heterogeneous expression of intellectual impairment, dysmorphic facies, musculoskeletal abnormalities and potential neurodevelopmental anomalies. We report the first case of natural progression in an adult patient who died at a young age of metastatic esophageal adenocarcinoma. Important learning points include the variable phenotypic expression of this microdeletion syndrome and the fact that clinicians must be thorough in investigating objective discrepancies in patients who cannot endorse classical symptoms.",
author = "Codipilly, {Don Chamil} and Gavrilova, {Ralitza M} and Tangalos, {Eric George}",
year = "2017",
doi = "10.1136/bcr-2016-218016",
language = "English (US)",
volume = "2017",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - De novo 2p16.1 microdeletion with metastatic esophageal adenocarcinoma

AU - Codipilly, Don Chamil

AU - Gavrilova, Ralitza M

AU - Tangalos, Eric George

PY - 2017

Y1 - 2017

N2 - Microdeletions involving chromosome 2p15-16.1 are a rare genetic abnormality and have been reported in 18 separate patients, mainly children, since 2007. This microdeletion syndrome is characterised by a heterogeneous expression of intellectual impairment, dysmorphic facies, musculoskeletal abnormalities and potential neurodevelopmental anomalies. We report the first case of natural progression in an adult patient who died at a young age of metastatic esophageal adenocarcinoma. Important learning points include the variable phenotypic expression of this microdeletion syndrome and the fact that clinicians must be thorough in investigating objective discrepancies in patients who cannot endorse classical symptoms.

AB - Microdeletions involving chromosome 2p15-16.1 are a rare genetic abnormality and have been reported in 18 separate patients, mainly children, since 2007. This microdeletion syndrome is characterised by a heterogeneous expression of intellectual impairment, dysmorphic facies, musculoskeletal abnormalities and potential neurodevelopmental anomalies. We report the first case of natural progression in an adult patient who died at a young age of metastatic esophageal adenocarcinoma. Important learning points include the variable phenotypic expression of this microdeletion syndrome and the fact that clinicians must be thorough in investigating objective discrepancies in patients who cannot endorse classical symptoms.

UR - http://www.scopus.com/inward/record.url?scp=85010427030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010427030&partnerID=8YFLogxK

U2 - 10.1136/bcr-2016-218016

DO - 10.1136/bcr-2016-218016

M3 - Article

C2 - 28108439

AN - SCOPUS:85010427030

VL - 2017

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

M1 - bcr2016218016

ER -